Neurosurgery:制定脑出血微创手术目标,以达到更佳疗效

2019-08-01 杨中华 脑血管病及重症文献导读

微创外科手术,包括立体定向导管rtPA溶解血凝块抽吸和清除血肿,是一项有希望的方法,以改善慕上脑出血的预后,降低致残率。最近发表了一项 III 期随机试验(MISTIE)发现这种方法能够降低死亡率,但是对主要终点未起到作用(1年 mRS 0-3)。

微创外科手术,包括立体定向导管rtPA溶解血凝块抽吸和清除血肿,是一项有希望的方法,以改善慕上脑出血的预后,降低致残率。最近发表了一项 III 期随机试验(MISTIE)发现这种方法能够降低死亡率,但是对主要终点未起到作用(1年 mRS 0-3)。

为了评价外科手术的操作以及手术操作对清除血肿和功能预后的作用,2019年6月来自于美国的Issam A. Awad等在NEUROSURGERY杂志上公布了他们对MISTIE 试验的后分析结果。

他们发现血肿清除越多的患者更容易达到 mRS 0-3分,并且mRS 0-3分获益的阈值为治疗结束时血肿体积<=15ml或清除血肿>=70%。死亡获益的阈值为治疗结束时血肿体积<=30ml,或清除血肿>=53%。最初的血肿体积、高血压病史、血肿形状不规则、阿替普酶的使用次数、外科方案的违背以及导管操作问题是未能达到<=15ml 目标的因素。经验丰富的外科医生或医院与避免发生不良血肿清除有关。

最终作者认为本文首次报道了降低死亡率和改善功能预后的血肿清除的阈值。为了实现外科手术的获益,应制定手术方案的目标,进行手术培训,提高手术技术,以及选择合适的患者。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1877740, encodeId=3a6518e77400f, content=<a href='/topic/show?id=b013169237f' target=_blank style='color:#2F92EE;'>#surgery#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16923, encryptionId=b013169237f, topicName=surgery)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Fri Mar 27 03:51:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021666, encodeId=4d9b20216666c, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sat Jun 13 17:51:00 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309492, encodeId=f61e13094922a, content=<a href='/topic/show?id=64ee5052ea7' target=_blank style='color:#2F92EE;'>#微创手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50527, encryptionId=64ee5052ea7, topicName=微创手术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Sat Aug 03 11:51:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317066, encodeId=c22c131e066ff, content=<a href='/topic/show?id=df8950505a2' target=_blank style='color:#2F92EE;'>#微创#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50505, encryptionId=df8950505a2, topicName=微创)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Sat Aug 03 11:51:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364512, encodeId=afcd1364512bc, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Aug 03 11:51:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032242, encodeId=f8851032242ac, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Thu Aug 01 23:51:00 CST 2019, time=2019-08-01, status=1, ipAttribution=)]
    2020-03-27 chg121
  2. [GetPortalCommentsPageByObjectIdResponse(id=1877740, encodeId=3a6518e77400f, content=<a href='/topic/show?id=b013169237f' target=_blank style='color:#2F92EE;'>#surgery#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16923, encryptionId=b013169237f, topicName=surgery)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Fri Mar 27 03:51:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021666, encodeId=4d9b20216666c, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sat Jun 13 17:51:00 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309492, encodeId=f61e13094922a, content=<a href='/topic/show?id=64ee5052ea7' target=_blank style='color:#2F92EE;'>#微创手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50527, encryptionId=64ee5052ea7, topicName=微创手术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Sat Aug 03 11:51:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317066, encodeId=c22c131e066ff, content=<a href='/topic/show?id=df8950505a2' target=_blank style='color:#2F92EE;'>#微创#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50505, encryptionId=df8950505a2, topicName=微创)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Sat Aug 03 11:51:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364512, encodeId=afcd1364512bc, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Aug 03 11:51:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032242, encodeId=f8851032242ac, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Thu Aug 01 23:51:00 CST 2019, time=2019-08-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1877740, encodeId=3a6518e77400f, content=<a href='/topic/show?id=b013169237f' target=_blank style='color:#2F92EE;'>#surgery#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16923, encryptionId=b013169237f, topicName=surgery)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Fri Mar 27 03:51:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021666, encodeId=4d9b20216666c, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sat Jun 13 17:51:00 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309492, encodeId=f61e13094922a, content=<a href='/topic/show?id=64ee5052ea7' target=_blank style='color:#2F92EE;'>#微创手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50527, encryptionId=64ee5052ea7, topicName=微创手术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Sat Aug 03 11:51:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317066, encodeId=c22c131e066ff, content=<a href='/topic/show?id=df8950505a2' target=_blank style='color:#2F92EE;'>#微创#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50505, encryptionId=df8950505a2, topicName=微创)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Sat Aug 03 11:51:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364512, encodeId=afcd1364512bc, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Aug 03 11:51:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032242, encodeId=f8851032242ac, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Thu Aug 01 23:51:00 CST 2019, time=2019-08-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1877740, encodeId=3a6518e77400f, content=<a href='/topic/show?id=b013169237f' target=_blank style='color:#2F92EE;'>#surgery#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16923, encryptionId=b013169237f, topicName=surgery)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Fri Mar 27 03:51:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021666, encodeId=4d9b20216666c, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sat Jun 13 17:51:00 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309492, encodeId=f61e13094922a, content=<a href='/topic/show?id=64ee5052ea7' target=_blank style='color:#2F92EE;'>#微创手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50527, encryptionId=64ee5052ea7, topicName=微创手术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Sat Aug 03 11:51:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317066, encodeId=c22c131e066ff, content=<a href='/topic/show?id=df8950505a2' target=_blank style='color:#2F92EE;'>#微创#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50505, encryptionId=df8950505a2, topicName=微创)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Sat Aug 03 11:51:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364512, encodeId=afcd1364512bc, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Aug 03 11:51:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032242, encodeId=f8851032242ac, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Thu Aug 01 23:51:00 CST 2019, time=2019-08-01, status=1, ipAttribution=)]
    2019-08-03 vera_1203
  5. [GetPortalCommentsPageByObjectIdResponse(id=1877740, encodeId=3a6518e77400f, content=<a href='/topic/show?id=b013169237f' target=_blank style='color:#2F92EE;'>#surgery#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16923, encryptionId=b013169237f, topicName=surgery)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Fri Mar 27 03:51:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021666, encodeId=4d9b20216666c, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sat Jun 13 17:51:00 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309492, encodeId=f61e13094922a, content=<a href='/topic/show?id=64ee5052ea7' target=_blank style='color:#2F92EE;'>#微创手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50527, encryptionId=64ee5052ea7, topicName=微创手术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Sat Aug 03 11:51:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317066, encodeId=c22c131e066ff, content=<a href='/topic/show?id=df8950505a2' target=_blank style='color:#2F92EE;'>#微创#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50505, encryptionId=df8950505a2, topicName=微创)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Sat Aug 03 11:51:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364512, encodeId=afcd1364512bc, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Aug 03 11:51:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032242, encodeId=f8851032242ac, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Thu Aug 01 23:51:00 CST 2019, time=2019-08-01, status=1, ipAttribution=)]
    2019-08-03 医者仁心
  6. [GetPortalCommentsPageByObjectIdResponse(id=1877740, encodeId=3a6518e77400f, content=<a href='/topic/show?id=b013169237f' target=_blank style='color:#2F92EE;'>#surgery#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16923, encryptionId=b013169237f, topicName=surgery)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Fri Mar 27 03:51:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021666, encodeId=4d9b20216666c, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sat Jun 13 17:51:00 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309492, encodeId=f61e13094922a, content=<a href='/topic/show?id=64ee5052ea7' target=_blank style='color:#2F92EE;'>#微创手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50527, encryptionId=64ee5052ea7, topicName=微创手术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Sat Aug 03 11:51:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317066, encodeId=c22c131e066ff, content=<a href='/topic/show?id=df8950505a2' target=_blank style='color:#2F92EE;'>#微创#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50505, encryptionId=df8950505a2, topicName=微创)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Sat Aug 03 11:51:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364512, encodeId=afcd1364512bc, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Aug 03 11:51:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032242, encodeId=f8851032242ac, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Thu Aug 01 23:51:00 CST 2019, time=2019-08-01, status=1, ipAttribution=)]
    2019-08-01 内科新手

    谢谢梅斯提供这么好的信息,学到很多

    0

相关资讯

Stroke:深部脑出血患者强化降压与血肿周围水肿扩张

由此可见,强化降压与深部ICH患者24小时PHER降低有关。PHER与所有深部ICH患者的结局无关,但与基底神经节ICH患者的预后不良有关。PHER可能是基底神经节ICH患者临床试验的临床相关终点。

Neurology:低密度脂蛋白胆固醇与脑出血风险

由此可见,当LDL-C<70mg/dL时,研究人员观察到较低LDL-C与较高ICH风险之间存在显著相关性,当LDL-C≥70mg/dL时,这种关联变得不显著。这些数据有助于确定动脉粥样硬化疾病患者和出血性卒中风险增加的患者的理想LDL范围,并指导未来降脂研究的计划。

以脑出血为首发症状的绒毛膜癌脑转移1例

女性,29 岁,因间断头痛5 年、加重1 周并抽搐1 次于2016年11月30日凌晨入院。5年来,病人出现间断头痛,自服止痛片后好转;1周前,自觉头痛加重,仍自服药物,未到医院就诊;2016年11月29日晚突然剧烈头痛,伴有恶心、呕吐数次,同时发生四肢抽搐,伴有双眼上翻,意识不清,数十分钟后自行缓解,急送我院急诊科,头部CT发现右颞脑出血,出血量约25 ml,周围水肿明显(图1A)。既往无高血压病

Lancet:中风4.5小时后接受阿替普酶溶栓仍可以获得较好的功能预后

中风发作后4.5-9小时的缺血性卒中患者接受阿替普酶治疗后,其功能预后优于安慰剂组。尽管阿替普酶治疗增加有症状脑出血风险,但这不能否定溶栓治疗的整体效益

Neurology:脑出血后低血红蛋白与血肿扩大

由此可见,需要进一步的研究来重复低入院血红蛋白水平与ICH后HE介导更差结局可能性增加之间的关联。如果得到证实,可能需要调查血红蛋白水平是否可以作为改善ICH结局的可调整治疗目标。

Lancet:脑出血幸存者是否可以接受抗血小板治疗?

研究认为,脑出血幸存患者接受抗血小板治疗不会增加复发性脑内出血风险